PT
Autoridade da Concorrência

Case details

Print
Merger control
Case reference
CCENT/2007/71 - ACTAVIS / ACTIVOS ROCHE
Acquiring
Actavis
Description
an international pharmaceuticals company especialising in the development, manufacture and marketing of generics; it is 100% owned by the Icelandic-registered company Actavis Group hf.
Acquired
Assets Roche
Description
All the assets relating to the products Roche Rapilyzin, Bezalip and Neotigason, such as patents, licences, trademarks, registrations, know-how, research and development materials, clinical and safety data, stocks, promotional and marketing materials and customer lists. The operation will not include the transfer of any manufacturing facilities. In Portugal, the only physical asset to be transferred consists of the stocks of finished products.
Sector
  • Extractive and manufacturing Industries
Activity (NACE)
  • C21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
Applicable legislation
Art. 9(1)(a) (Law 18)
Notification thresholds
Market share
Type of merger
Horizontal
Cooperation with sector regulators
Status
Closed
Type of Investigation
Phase 1
AdC’s decision
Case description
Notified on 15 October 2007, with effect on 7 November 2007, this merger consists of the acquisition, by the undertaking Actavis Group PTC ehf (hereafter ACTAVIS), of exclusive control of a set of Assets relating to the products Roche Rapilyzin, Bezalip and Neotigason (hereafter Roche Assets).
Timeline
2007-12-10
Competition Authority authorises the acquisition of exclusive control of a range of Roche Assets relating to the Roche products Rapilysin, Bezalip and Neotigason
2007-11-13
Publication of the announcement
Click here to see your activities